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Accumulation of -amyloid (A) peptides in the cerebral cortex is considered a key event in the pathogenesis of Alzheimer’s disease
(AD). Presenilin 1 (PS1) plays an essential role in the -secretase cleavage of the amyloid precursor protein (APP) and the generation of
A peptides. Reduction of A generation via the inhibition of -secretase activity, therefore, has been proposed as a therapeutic
approach for AD. In this study, we examined whether genetic inactivation of PS1 in postnatal forebrain-restricted conditional knock-out
(PS1 cKO) mice can prevent the accumulation of A peptides and ameliorate cognitive deficits exhibited by an amyloid mouse model that
overexpresses human mutant APP. We found that conditional inactivation of PS1 in APP transgenic mice (PS1 cKO;APP Tg) effectively
prevented the accumulation of A peptides and formation of amyloid plaques and inflammatory responses, although it also caused an
age-related accumulation of C-terminal fragments of APP. Short-term PS1 inactivation in young PS1 cKO;APP Tg mice rescued deficits in
contextual fear conditioning and serial spatial reversal learning in a water maze, which were associated with APP Tg mice. Longer-term
PS1 inactivation in older PS1 cKO;APP Tg mice, however, failed to rescue the contextual memory and hippocampal synaptic deficits and
had a decreasing ameliorative effect on the spatial memory impairment. These results reveal that in vivo reduction of A via the
inactivation of PS1 effectively prevents amyloid-associated neuropathological changes and can, but only temporarily, improve cognitive
impairments in APP transgenic mice.
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Introduction
Alzheimer’s disease (AD) is an age-related neurodegenerative
disorder in which progressive memory loss is accompanied by
cognitive decline. Neuropathologically, AD is characterized by a
progressive loss of synapses and neurons as well as the presence of
amyloid plaques and neurofibrillary tangles. Mutations in the
genes encoding -amyloid precursor protein (APP) and preseni-
lins are linked to familial AD (FAD) (Hutton and Hardy, 1997).
According to the “amyloid cascade” hypothesis, accumulation of
-amyloid (A) peptides, which are the main constituents of
amyloid plaques, is the key event initiating AD pathogenesis
(Hardy and Selkoe, 2002).
Transgenic (Tg) mice overexpressing mutant forms of APP
reproduce several key neuropathological features of AD, such as
amyloid plaques and inflammatory responses (Games et al., 1995;
Borchelt et al., 1996; Hsiao et al., 1996; Masliah et al., 1996;
Sturchler-Pierrat et al., 1997; Mucke et al., 2000). In addition,
APP transgenic mice can exhibit age-related impairments of hip-
pocampal synaptic plasticity and learning and memory (Hsiao et
al., 1996; Chapman et al., 1999; G. Chen et al., 2000; Morgan et
al., 2000; Koistinaho et al., 2001; Corcoran et al., 2002). The
synaptic and cognitive deficits often appear before amyloid
plaque deposition and synaptic loss (Hsia et al., 1999; Larson et
al., 1999; Koistinaho et al., 2001).
If A accumulation is causal with respect to progression of the
disease, limiting its accumulation should be beneficial therapeu-
tically. An experimental test of this idea would be to limit the
accumulation of A at the point of synthesis or degradation. A
peptides are generated by two sequential proteolytic cleavages of
APP mediated by - and -secretases. -Secretase [-site APP-
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cleaving enzyme (BACE)] is an aspartyl protease that cleaves APP
to generate the -C-terminal fragment (-C-TF) of APP (Vassar
et al., 1999). Thus one route to limit the accumulation of A
would be to block or inhibit BACE (Ohno et al., 2004). An alter-
native route is via -secretase, or presenilin, an essential compo-
nent of the -secretase complex, which further cleaves -C-TF to
generate A. This has led to the hypothesis that targeting prese-
nilin function by -secretase inhibitors also may be a suitable
therapeutic strategy for AD (Hardy and Selkoe, 2002).
A major problem with this strategy is that presenilin 1 (PS1)
plays essential roles in vivo (Wong et al., 1997; Xia et al., 2001; Pan
et al., 2004), including neuronal differentiation and migration
during embryonic development (Shen et al., 1997; Handler et al.,
2000; Wines-Samuelson et al., 2005). However, PS1 conditional
knock-out (PS1 cKO) mice, in which PS1 inactivation is re-
stricted to the postnatal forebrain, show reduced A generation
and only subtle spatial memory impairment (Yu et al., 2001).
Nevertheless, complete inactivation of both presenilins in the
adult cerebral cortex results in hippocampal memory and synap-
tic plasticity impairments, followed by progressive neurodegen-
eration (Saura et al., 2004). Based on these results, we hypothe-
sized that partial, but not complete, -secretase inactivation may
prevent amyloid-related neuropathological changes and amelio-
rate the hippocampal-dependent learning deficits exhibited by
APP transgenic mice. To test this hypothesis, we used here a
multidisciplinary approach to examine the effects of partial inhi-
bition of -secretase activity on amyloid-related neuropathology
and cognitive impairments associated with APP transgenic mice
via PS1 inactivation.
Materials and Methods
Mice. Generation of PS1 cKO and APP transgenic mice (APP Tg; J20 line)
has been described previously (Mucke et al., 2000; Yu et al., 2001). To
generate PS1 cKO;APP Tg mice, we first crossed APP transgenic mice,
which were maintained in the hybrid background of C57BL/6 and DBA,
with homozygous floxed PS1 ( fPS1/fPS1) mice, which expressed normal
levels of PS1 and were maintained in the hybrid background of C57BL/6
and 129, to obtain the fPS1/;APP Tg mice, which then were bred to
fPS1/fPS1 to obtain fPS1/fPS1;APP Tg mice. fPS1/fPS1;APP Tg mice then
were bred to fPS1/fPS1;CaM-Cre (PS1 cKO) to obtain fPS1/fPS1;CaM-
Cre;APP (PS1 cKO;APP Tg) mice. The mice used in the study, PS1 cKO;
APP Tg, PS1 cKO, APP Tg, and control mice, were littermates obtained
from the cross between PS1 cKO;APP Tg and control ( fPS1/fPS1) mice.
The genetic background of all mice used in the study was in the same
hybrid background of C57BL/6, 129, and DBA. Experimenters of the
behavioral tests and the electrophysiological analysis were blind to the
genotypes of the mice.
Western blotting and ELISA analyses. For biochemical analysis, the
mice cortices were dissected and homogenized in cold lysis buffer [con-
sisting of (in mM) 50 Tris-HCl, pH 7.4, 150 NaCl, 1 EDTA plus 1%
NP-40, and 0.5% Triton X-100] containing protease and phosphatase
inhibitors (Sigma, St. Louis, MO). Lysates were cleared by centrifugation
(12,000 rpm for 15 min), and the same amount of total protein was
resolved on SDS-PAGE. Polyvinylidene difluoride membranes were in-
cubated with antibodies against PS1 (PS1NT, 1:12,000; Calbiochem, La
Jolla, CA), APP (Saeko antiserum APP665– 695; 1:7500), phosphorylated
tau (Ser 202; CP13, 1:250), and -actin (1:20,000; Abcam, Cambridge,
UK) (Yu et al., 2001; Saura et al., 2004). For ELISAs, the total (soluble and
insoluble) human A40 and A42 peptides from the cortex of APP Tg
and PS1 cKO;APP Tg mice (n  3– 8) were measured by the 2G3/3D6
and 21F12/3D6 sandwich ELISA, respectively (Johnson-Wood et al.,
1997).
Immunohistochemistry and immunogold electron microscopy. Paraffin-
embedded brain sections (10 m) were deparaffinized, alcohol-
dehydrated, and immunostained with an A antiserum (R1282; 1:1000)
or monoclonal glial fibrillary acidic protein (GFAP; 1:500; Sigma) or
CD45 (1:5000; Serotec, Raleigh, NC) antibodies as described previously
(Stoltzner et al., 2000; Saura et al., 2004). Brain sections were incubated
with biotinylated secondary antibodies and developed by using the per-
oxidase avidin– biotin reagent and the Vectastain Elite ABC kit (Vector
Laboratories, Burlingame, CA). For double immunostaining, the sec-
tions were immunostained with C7 antiserum (APP676 – 695; 1:1000) and
monoclonal synaptophysin (1:200; Sigma), NMDA receptor 1
(NMDAR1; 1:200; Chemicon, Temecula, CA), microtubule-activated
protein 2 (MAP2; 1:250; Sigma), or R1282 and phosphorylated tau
(Ser 202/Thr 205) (AT-8, 1:50; Innogenetics, Gent, Belgium) antibodies
and were incubated with Alexa Fluor 488 or 594 secondary antibodies
(Molecular Probes, Eugene, OR) (Saura et al., 2004). Images were ana-
lyzed with a Zeiss (Oberkochen, Germany) 510 confocal laser-scanning
microscope.
Procedures for immunogold electron microscopic analysis have been
described previously (Takahashi et al., 2002). For immunogold labeling,
the free-floating sections were incubated with 369 antibody (APP649 – 695)
by the immunogold-silver procedure and goat anti-rabbit IgG conju-
gated to 1 nm gold particles (Amersham Biosciences, Arlington, IL) in
0.01% gelatin and 0.08% bovine serum albumin in PBS. Transmission
electron microscopy was performed on a Philips CM10 electron micro-
scope at the Division of Neurobiology of Weill–Cornell Medical College
(New York, NY).
Contextual fear conditioning. For contextual fear conditioning, the
mice were placed within the conditioning chamber for 3 min before the
onset of the unconditioned stimulus (US; footshock; 1 s/1 mA) to allow
them to develop a representation of the context via exploration. After the
shock, they then were left in the chamber for 2 min (immediate freezing)
and returned to the home cages. Conditioning was tested 24 h after
training for 4 min in the same conditioning chamber. Freezing response
was scored by using the FreezeFrame automated system (Actimetrics,
Wilmette, IL).
Water maze. Mice used for all behavioral tests were littermates and
were 3 and 15–17 months of age. The serial spatial reversal task was
performed in a circular pool (2 m in diameter) with a hidden platform
(20 cm in diameter) (G. Chen et al., 2000). For the visible cue task, the
pool was surrounded with white curtains to hide the extramaze cues, and
the platform was marked with a dark cylinder. Each mouse was given
four trials daily for 5 d, with a maximum trial duration of 90 s and an
intertrial interval of 10 min. For the serial spatial learning to a hidden
platform, each mouse was given a maximum of eight trials daily before
reaching the criterion of three trials in a row with an average escape
latency of 20 s. After the criterion was reached, the platform was moved
to a new position the next day, and the training started again. An initial
series of five different hidden platform locations was used, and the mice
were allowed to take as many days as they needed to learn each of the
platform locations. With the use of additional platform locations, the
maximum number that the animals could learn in 10 d was used as a
measure of learning capacity. The movement of the mice was monitored
by an automated tracking system (Watermaze; Actimetrics).
Electrophysiology. Hippocampal slice preparation was performed as
described previously (Yu et al., 2001). Stimulation (200 ms) pulses were
delivered with a bipolar concentric metal electrode. Synaptic strength
was quantified as the initial slope of field potentials recorded with artifi-
cial CSF-filled microelectrodes (1–2 M). Baseline responses were col-
lected at 0.07 Hz with a stimulation intensity that yielded a half-maximal
response. Long-term potentiation (LTP) was obtained by five episodes of
theta burst stimulation (TBS) delivered at 0.1 Hz. Each episode con-
tained 10 stimulus trains delivered at 5 Hz, and each train consisted of
four pulses at 100 Hz. Average responses (mean  SEM) were expressed
as a percentage of pre-TBS baseline response (at least 10 min of stable
responses). A repeated-measures ANOVA was used to assess statistical
significance.
Results
To evaluate the consequence of partial -secretase inactivation
on the neuropathological changes and memory impairments in
APP transgenic mice, we crossed PS1 cKO mice (Yu et al., 2001)
with APP Tg mice, which overexpress a human APP containing
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the Swedish (K670N/M671L) and Indiana (V717F) mutations
(Swe/Ind) (Mucke et al., 2000), to generate double-mutant PS1
cKO;APP Tg mice. The APP transgenic mice have been shown
previously to develop amyloid plaques and other AD-like fea-
tures in an age-dependent manner (Mucke et al., 2000).
Accumulation of APP C-TFs in synaptic terminals
Using Western blot analysis, we first confirmed the marked re-
duction of PS1 in the cerebral cortex of PS1 cKO;APP Tg mice at
2, 6, and 17 months of age (Fig. 1). The residual level of PS1 in the
cortex of PS1 cKO;APP Tg mice likely is attributable to the nor-
mal PS1 expression in glia and interneurons, where PS1 expres-
sion is not targeted to eliminate in PS1 cKO mice (Yu et al., 2001).
We next examined the consequence of PS1 inactivation on the
proteolytic processing of APP. Western blot analysis showed an
increase (approximately twofold) of full-length APP in APP Tg
and PS1 cKO;APP Tg mice compared with nontransgenic con-
trols at 2, 6, and 17 months of age (Fig. 1). The level of APP C-TFs
was increased markedly in the cortex of PS1 cKO;APP Tg mice
relative to APP Tg mice at 2, 6, and 17 months of age (Fig. 1).
Similarly, the level of APP C-TFs was increased in PS1 cKO mice,
compared with the control, at all ages. Furthermore, the increase
in APP C-TFs was higher at 6 and 17 months of age relative to that
at 2 months of age (n  3– 4). These results indicate that there is
an age-dependent increase in APP C-TFs in the cortex of PS1
cKO;APP Tg mice.
To determine the subcellular localization of the accumulated
APP C-TFs in PS1 cKO;APP Tg mice, we performed immunohis-
tological analysis by using the C7 antibody on PS1 cKO;APP Tg
mice at 6 months of age and littermate APP Tg mice as controls.
The C7 antibody was raised against the C-terminal region of APP,
which can recognize both full-length APP and C-TFs of APP. We
found that the C7 immunoreactivity was localized mainly in the
cell body of hippocampal neurons in APP Tg mice, whereas in
PS1 cKO;APP Tg mice, the C7 immunoreactivity was mostly in
neuronal processes, suggesting an ectopic localization of the ac-
cumulated APP C-TFs in the absence of PS1 (Fig. 2A–C). To
address this issue further, we performed confocal microscopy
analysis by using the C7 antibody and antibodies specific for
MAP2 (somatodendritic), NMDAR1 (a postsynaptic marker), or
synaptophysin (a presynaptic marker). We found that the C7
(green) and MAP2 (red) immunoreactivity were not colocalized
in PS1 cKO;APP Tg mice (Fig. 2A). The C7 immunoreactivity,
however, did overlap partially (yellow) with the NMDAR1 im-
munoreactivity in PS1 cKO;APP Tg mice, although there was
some C7 immunoreactivity (green) that did not overlap with the
NR1 immunoreactivity (red) (Fig. 2B). In contrast, the C7 im-
munoreactivity overlapped almost entirely with synaptophysin,
suggesting that APP C-TFs were localized primarily to the pre-
synaptic terminal (Fig. 2C).
To confirm the synaptic localization of APP C-TFs, we also
performed electron microscopy analysis by using the 369 anti-
body, which is also specific for the C-terminal region of APP. We
found that the 369 immunoreactivity was localized predomi-
nantly in the presynaptic terminal of cortical and hippocampal
neurons in PS1 cKO;APP Tg brains, whereas no immunoreactiv-
ity was detected in nontransgenic control or APP Tg mice (Fig.
2D) (data not shown). These results indicate that partial inhibi-
tion of -secretase activity by PS1 inactivation causes an accumu-
lation of APP C-TFs in the presynaptic terminal.
Prevention of amyloid-related neuropathological changes
To determine whether increased levels of APP C-TFs were ac-
companied by a decreased production of A peptides, we mea-
sured the amount of total (soluble and insoluble) human A
peptides in the cerebral cortex of PS1 cKO;APP Tg and APP Tg
mice at 2–3, 6, and 17 months of age. Our previous study has
shown a reduction of endogenous mouse A peptides in the
cortices of PS1 cKO mice (Yu et al., 2001). Sandwich ELISA re-
vealed that A peptides accumulated in an age-dependent man-
ner in the cerebral cortex of APP Tg mice, and the increase in
A42 was more marked than A40 at 6 and 17 months of age (Fig.
3). In the cortex of PS1 cKO;APP Tg mice, the cortical A40 levels
were reduced significantly at 2–3 months of age (58%; p 
0.006; n  8), 6 months of age (78%; p  0.0001; n  7), and 17
months of age (96%; p  0.0001; n  3). Similarly, levels of
A42 were reduced at 2–3 months of age (55%; p  0.002; n 
8), 6 months of age (90%; p  0.0001; n  7), and 17 months of
age (99%; p  0.0001; n  3). These results indicate that inac-
tivation of PS1 resulted in reductions in the levels of A peptides
and prevented age-dependent accumulation of A peptides.
Histological analysis with an antibody (R1282) specific for A
confirmed the age-dependent deposition of amyloid plaques in
the hippocampus and neocortex of APP transgenic mice starting
at 5 months of age (Fig. 4A), as reported previously (Mucke et
al., 2000). In the cortex of PS1 cKO;APP Tg mice, the R1282
immunoreactivity (Fig. 4A) and thioflavine S staining (data not
shown), which recognizes fibrillar A, were absent, indicating the
lack of amyloid plaque formation in these mice. Similar results
were obtained from an analysis of PS1 cKO;APP Tg mice at 12
months of age (data not shown). These results demonstrate that
targeting PS1 function in the adult brain effectively prevents
amyloid plaque formation in APP transgenic mice.
In addition to amyloid deposition, inflammatory responses
such as astrogliosis, microgliosis, and dystrophic neurites are
prominent neuropathological features in APP transgenic mice
(Masliah et al., 1996; Frautschy et al., 1998; Matsuoka et al.,
2001). Reactive astrocytes and activated microglial cells labeled
by GFAP and CD45 immunoreactivity, respectively, were present
in the hippocampus of APP Tg mice but absent in that of PS1
cKO;APP Tg mice at 6 months of age (Fig. 4B). Similarly, dystro-
phic neurites labeled with antibodies against phosphorylated tau
(AT-8) were present in the cortices of APP Tg mice but absent in
PS1 cKO;APP Tg mice (Fig. 4C). Western blot analysis also indi-
cated a modest but statistically insignificant decrease in the level
of phosphorylated tau (Ser 202) in cortical lysates of PS1 cKO;APP
Figure 1. Age-dependent accumulation of APP C-TFs in PS1 cKO;APP Tg mice. Levels of APP,
APP C-TFs, and PS1 in cortical lysates of control, PS1 cKO, APP Tg, and PS1 cKO;APP Tg mice at 2,
6, and 17 months of age were analyzed by Western blotting with the use of antibodies specific
for the C terminal of APP (Saeko) or PS1. An antibody specific for -actin was used as a loading
control. Levels of APP C-TFs in PS1 cKO;APP Tg mice were increased at 6 and 17 months of age
compared with 2 months of age.
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Tg mice compared with that in APP Tg
mice at 6 months of age (APP Tg, 100 
28%; PS1 cKO;APP Tg, 70.3  2.7%; p 
0.05; n  3). This likely is attributable to
the fact that dystrophic neurites immuno-
reactive for phosphorylated tau were re-
stricted to areas in or surrounding com-
pact amyloid plaques in APP Tg mice and
that the number of compact amyloid
plaques was low and varied among individ-
ual mice at this age. Overall, these results
demonstrate that inactivation of PS1 in
APP transgenic mice prevented amyloid-
associated inflammatory responses and
neuritic degeneration.
Age-dependent rescue of contextual
memory deficits
To determine whether reduced levels of
A peptides and the absence of amyloid
plaques in PS1 cKO;APP Tg mice were as-
sociated with the rescue of cognitive defi-
cits, we examined littermate PS1 cKO;APP
Tg, APP Tg, PS1 cKO, and control mice by
using two behavioral tasks assessing their
learning and memory. Although levels of
A peptides are similar in PS1 cKO;APP
Tg mice between 2–3 and 6 months of age,
levels of APP C-TFs accumulate with age.
This accumulation may limit the extent of
cognitive rescue. We therefore tested these
mice at different ages (3 and 6 months).
We first tested all four genotypic
groups in contextual fear conditioning, in
which memory can be acquired in a single
training session. In contextual fear condi-
tioning, the mice learn to associate a con-
ditioned stimulus (CS; test chamber) with
a US (footshock) (Phillips and LeDoux,
1992). After the pairing of CS and US, a
robust associative memory of the CS–US is
formed such that the CS alone can elicit a
fear response (e.g., freezing). At 3 months
of age, PS1 cKO;APP Tg, APP Tg, PS1
cKO, and control mice displayed similar
levels of freezing immediately after train-
ing (Fig. 5A). However, APP Tg mice
showed significantly reduced levels of
freezing to the context 24 h after training
compared with the other three genotypic
groups (F(3,31)  3.39; p  0.03). Post hoc
analysis revealed a significant reduction in
freezing responses in APP Tg mice (29.3 
7.4%; n  7) compared with control
(50.1  3.0%; n  10), PS1 cKO (49.0 
5.2%; n  9), and PS1 cKO;APP Tg
(48.1  6.2%; n  9) mice ( p  0.032).
The fact that PS1 cKO;APP Tg mice per-
formed as well as control mice ( p  0.42)
suggests that inactivation of PS1 had pre-
vented the impairment of contextual fear
memory normally displayed by APP trans-
genic mice at this age.
Figure 2. Accumulation of APP C-TFs in presynaptic terminals of PS1 cKO;APP Tg mice. A, Confocal microscopic images showing
a marked increase in APP C-TFs recognized by C7 immunoreactivity (green) and a lack of colocalization (yellow) between the C7
immunoreactivity and the somatodendritic marker MAP2 immunoreactivity (red) in CA1 pyramidal neurons of 6-month-old PS1
cKO;APP Tg mice. B, Confocal microscopic images showing an increase in APP C-TFs recognized by C7 immunoreactivity (green)
and its partial colocalization (yellow) with the postsynaptic marker NMDAR1 immunoreactivity (NR1; red) in CA1 pyramidal
neurons of PS1 cKO;APP Tg mice. C, Confocal microscopic images showing a marked increase in APP C-TFs recognized by C7
immunoreactivity (green) and its abundant colocalization (yellow) with the presynaptic marker synaptophysin immunoreactivity
(Syn; red) in CA1 pyramidal neurons of PS1 cKO;APP Tg mice. D, Electron microscopic images showing higher levels of accumula-
tion of APP C-TFs in presynaptic compartments (arrowheads) compared with postsynaptic compartments (asterisk) in CA1 (top)
and cortical (bottom) neurons from PS1 cKO;APP Tg mice at 6 months of age. Magnification: top, 19,000; bottom, 13,500.
Scale bars: A–C, 25 m; D, 500 nm.
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A different pattern was observed at 6 months of age. All four
genotypic groups again showed similar levels of freezing re-
sponses immediately after the footshock (Fig. 5B). However, in
the memory retention test conducted 24 h after the initial train-
ing, there was no longer any rescue associated with the condi-
tional PS1 inactivation. The overall analysis showed a significant
main effect of genotype in freezing responses 24 h after the initial
training session (F(3,43)  9.0; p  0.0001). Post hoc analysis re-
vealed that the freezing responses shown by APP Tg (28.1 
3.4%; n  12) and PS1 cKO;APP Tg (22.8  4.4%; n  13) mice
were reduced significantly compared with control (50.0  5.04%;
n  16) and PS1 cKO (48.8  5.1%; n  6) mice ( p  0.02) (Fig.
5B). These results indicate that the ability of PS1 cKO;APP Tg
mice to display a rescue of the memory deficit shown by APP
transgenic mice deteriorated with age.
Age-dependent rescue of serial spatial learning
Previously, platelet-derived growth factor promoter APP
(PDAPP) mice have been shown to exhibit both age-independent
and age-related and amyloid plaque-related deficits in serial spa-
tial learning in the water maze (G. Chen et al., 2000). The age-
related component of these changes in learning ability occurred
gradually over the range of 8 –16 months in the PDAPP mice. To
determine whether the APP transgenic mice used in our study
exhibit similar age-related changes in learning and whether these
could be rescued by PS1 inactivation, we used the identical train-
ing protocol. The only change was to start testing at a younger age
(3 months) at which the APP transgenic mice used in this study
previously exhibited an impairment in contextual fear condition-
ing. The full battery of tests (see Materials and Methods) con-
sisted of cued navigation (5 d), followed by training-to-criterion
in each of five different successively learned spatial locations and
then continued training for 10 d to obtain a measure of learning
capacity.
In the cue task, all genotypic groups at 3 and 15–17 months of
age showed excellent learning to locate a visible platform, with
rapidly declining swim latencies across days (Greenhouse–Geis-
ser correction for multiple comparisons; F  99.42; p  0.001)
(Fig. 6A,B). Thus there were no gross sensorimotor abnormali-
ties that might have limited their capacity to learn the more com-
plex hidden platform task that was trained next. In the serial
spatial learning task, the escape latency is measured on each swim
trial, but the primary measures for analysis are trials-to-criterion
and learning capacity. Trials-to-criterion is the number of trials
taken to learn each of the five successive spatial locations to the
criterion of three trials averaging 20 s. Learning capacity is the total
number of spatial locations learned in 10 d. Although distinct, these
measures are related and thus not strictly independent.
Analyses of trials-to-criterion performed separately for young
and old mice revealed overall group differences in the young
mice, but only a trend in the old mice (for young, F  5.24, df
3/43, p  0.005; for old, F  2.82, df 3/40, 0.10  p  0.05). The
pattern in the young mice revealed no significant difference
among PS1 cKO;APP Tg, PS1 cKO, and control groups ( p 
0.10), with all three groups taking fewer trials to learn the five
platform locations than the APP Tg group (F  18.00; df 1/43;
p  0.001) (Fig. 6C). Thus, as in contextual fear conditioning,
PS1 cKO;APP Tg mice at 3 months of age showed a rescue of the
impaired phenotype displayed by APP Tg mice. However, as
shown in Figure 6D, this rescue effect was weaker in the older
mice. In these animals, the performance of the APP Tg, PS1 cKO;
APP Tg, and PS1 cKO mice did not differ from each other ( p 
0.10), but the average performance of these groups was poorer than
that shown by the control group (F  5.25; df 1/40; p  0.05).
Next we analyzed the learning capacity of mice at 3 and 15–17
months of age (i.e., the number of serial spatial locations they
could learn in 10 d). These analyses showed overall differences
across groups in both the young and old mice (for young, F 
4.99, df 3/43, p  0.005; for old, F  4.19, df 3/40, p  0.05). In
the young mice, orthogonal comparisons showed a rescue effect
in the PS1 cKO;APP Tg mice, which performed as well as control
and PS1 cKO mice and better than the APP Tg group ( p  0.001)
(Fig. 6E). In the older mice, the APP Tg, PS1 cKO;APP Tg, and
PS1 cKO groups did not differ significantly, but the average per-
formance of these three groups was significantly poorer than for
controls (F  9.23; df 1/40; p  0.01) (Fig. 6F). We conclude that,
in the serial spatial learning task, which displays an age-related
decline in learning by control and APP Tg mice, inactivation of
PS1 ameliorates the learning deficit in young APP Tg mice, but
this apparent rescue of learning ability deteriorates with age.
Failure to rescue synaptic dysfunction
It has been reported that transgenic mice overexpressing human
mutant APP exhibit impaired synaptic transmission and/or plas-
ticity (Chapman et al., 1999; Fitzjohn et al., 2001). To determine
whether inactivation of PS1 in PS1 cKO;APP Tg mice can rescue
the hippocampal synaptic deficits associated with APP Tg mice,
we examined synaptic transmission and plasticity in the Schaffer
collateral pathway in control, APP Tg, and PS1 cKO;APP Tg mice
at 6 months of age [PS1 cKO mice were reported previously by Yu
et al. (2001)], because at this age both APP Tg and PS1 cKO;APP
Tg mice exhibited contextual memory impairments (Fig. 5B). To
measure basal synaptic transmission, we first determined input/
output (I/O) curves in acute hippocampal slices by plotting the
amplitude of the fiber volley (FV), which is a measure of the
number of recruited axons, versus the initial slope of the evoked
field EPSP (fEPSP). ANOVA of the average of the FV–fEPSP
slope showed a significant main effect of genotype (F(2,84)  6.19;
p  0.003). Post hoc analysis revealed reduced basal synaptic
transmission in APP Tg and PS1 cKO;APP Tg mice compared
with controls ( p  0.02) (Fig. 7A). Paired pulse facilitation
(PPF), a presynaptic form of short-term plasticity that correlates
inversely with the probability of transmitter release, was similar
in all genotypic groups (F(2,12)  1.99; p  0.14) (Fig. 7B). These
results are consistent with previous reports showing reduced syn-
aptic transmission and unchanged PPF in similar APP Tg mice
(Hsia et al., 1999; Jolas et al., 2002). Our previous study has
shown that induction of LTP was normal in PS1 cKO mice (Yu et
al., 2001); we therefore examined synaptic plasticity in hip-
Figure 3. Reduced accumulation of A peptides in PS1 cKO;APP Tg mice. Levels of A40 (A)
and A42 (B) in cortical lysates of APP Tg and PS1 cKO;APP Tg mice were quantified by ELISA. In
APP Tg mice, the levels of A40 and A42 were increased from 2 to 17 months of age; levels of
A42 were higher than those of A40 at 6 and 17 months of age. In the PS1 cKO;APP Tg mice,
A40 and A42 were reduced significantly at all ages. Data represent the mean  SEM; pmol/g
signifies picomoles of A per gram of cortex. *p  0.01; **p  0.001; ***p  0.0001.
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pocampal slices from APP Tg and PS1
cKO;APP Tg mice and littermate controls
by inducing LTP with TBS. The initial in-
duction of LTP was reduced in APP Tg
(155.3  11.1) and PS1 cKO;APP Tg
(154.3  8.7) mice compared with control
mice (180.4  8.1) (Fig. 7C). Repeated-
measures ANOVA of the magnitude of
LTP showed a significant main effect of
genotype (F(2,212)  4.65; p  0.05), indi-
cating that LTP was impaired in APP Tg
and PS1 cKO;APP Tg mice.
To determine whether basal synaptic
transmission and LTP changes in APP Tg
and PS1 cKO;APP Tg mice were age de-
pendent, we also performed electrophysi-
ological recordings in younger mice at 3
months of age. ANOVA of the FV–fEPSP
slope indicated similar responses in
younger control (7.74  0.54; n  5), APP
Tg (8.13  0.65; n  5), and PS1 cKO;APP
Tg (8.27  0.58; n  5) mice (F(2,64) 
0.21; p  0.81), suggesting normal basal
synaptic transmission in mutant mice at
this age (Fig. 7D). Similar to the older age,
APP Tg and PS1 cKO;APP Tg mice at 3
months of age showed PPF at each inter-
stimulus interval that was similar to that
seen for control mice (F(2,12)  2.1; p 
0.13), indicating intact presynaptic short-
term plasticity in these mutant mice (Fig.
7E). Induction of LTP in CA1 hippocam-
pal synapses of younger APP Tg and PS1
cKO;APP Tg mice elicited larger responses
than in control mice (Fig. 7F). Repeated-
measures ANOVA of the magnitude of
LTP in the last 10 min showed a significant
main effect of genotype (F(2,253)  47.9;
p  0.0001), indicating an enhancement of
LTP induction in younger APP Tg and PS1
cKO;APP Tg mice at 3 months of age. This
enhancement of LTP that occurs before
amyloid deposition has been observed pre-
viously in the CRND8 transgenic mouse,
which also overexpresses the mutant
APPSwe/Ind and develops hippocampal-de-
pendent cognitive deficits (Janus et al., 2000;
Jolas et al., 2002). Although the exact mech-
anism or mechanisms underlying the age-
dependent synaptic plasticity alterations in
these mutants are unclear, varying levels of
A and APP C-TFs in APP Tg and PS1 cKO;
APP Tg mice at these two ages may account for such a phenotype.
Previous in vitro studies have shown both reduction and enhance-
ment of LTP after acute perfusion of A in hippocampal slices (Wu
et al., 1995; Q. S. Chen et al., 2000). Secreted forms of APP also have
been found to increase LTP (Ishida et al., 1997).
Discussion
Genetic and pharmacological approaches designed to prevent or
slow cognitive decline in AD should be evaluated in animal mod-
els by a variety of appropriate behavioral tests of learning and
memory. The possible causal role of A in AD pathogenesis raises
the possibility of therapeutic strategies based on processes that
regulate the level of A peptides. Our previous finding that inac-
tivation of PS1 in the postnatal forebrain results in a significant
reduction of A peptides without major deleterious conse-
quences in mice supports the view that selective inhibition of PS1
or -secretase activity may represent a suitable therapeutic strat-
egy for AD (Yu et al., 2001). Our recent investigations have re-
vealed, however, that disruption of PS1 and PS2 in the mouse
postnatal forebrain causes synaptic and memory deficits and age-
dependent neurodegeneration (Saura et al., 2004). Because the
pharmacological targeting of presenilin function or -secretase
Figure 4. Absence of amyloid plaques and inflammation in PS1 cKO;APP Tg mice. A, Sagittal brain sections from APP Tg and PS1
cKO;APP Tg mice were stained with an A antibody (R1282) to reveal the presence of amyloid plaques in the hippocampus of APP
Tg mice and their absence in PS1 cKO;APP Tg mice at 6 months of age. Higher-power views of the boxed areas in the top panels are
shown at the bottom. CA1 and CA3, CA1 and CA3 fields of the hippocampus, respectively; DG, dentate gyrus. Scale bar, 10 m. B,
Brain sections of APP Tg and PS1 cKO;APP Tg mice at 6 months of age were stained with antibodies specific for CD45 and GFAP.
Activated microglial cells labeled by CD45 antibody and reactive astrocytes, which express high levels of GFAP and extend elabo-
rate processes, are found only in the hippocampus of APP Tg mice, but not in PS1 cKO;APP Tg mice. Scale bar, 10 m. C, Confocal
microscopy analysis of APP Tg and PS1 cKO;APP Tg brain sections double-labeled with antibodies for phosphorylated tau (green)
and A (red). Dystrophic axons immunoreactive for phosphorylated tau either extend into plaques (arrow) or remain in the
surrounding area of the plaque (arrowheads) in the hippocampus of APP Tg mice, whereas the PS1 cKO;APP Tg brain lacks such
processes. Scale bar, 10 m.
Figure 5. Age-dependent rescue of contextual memory in PS1 cKO;APP Tg mice. A, Control (n  10), PS1 cKO (n  9), APP Tg
(n  7), and PS1 cKO;APP Tg (n  9) mice at 3 months of age were tested in the one-shock contextual fear conditioning task. All
four groups showed similar levels of freezing immediately after the footshock. Control, PS1 cKO, and PS1 cKO;APP Tg mice showed
similar levels of freezing (50%) at 24 h, whereas APP Tg mice exhibited significantly reduced levels of freezing (30%)
(F(3,31) 3.39; *p 0.03). B, Control (n 16), PS1 cKO (n 6), APP Tg (n 12), and PS1 cKO;APP Tg (n 13) mice at 6 months
of age were tested in the one-shock contextual fear conditioning task. All four groups showed similar levels of freezing immedi-
ately after the footshock. However, APP Tg and PS1 cKO;APP Tg mice showed reduced levels of freezing when compared with
control and PS1 cKO mice at 24 h (F(3,43)  9.0; **p  0.0001). Data represent the mean  SEM.
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activity is likely to lead to partial rather than complete inhibition
of -secretase, a more relevant genetic mouse model of
-secretase inhibition is a partial -secretase inactivation as in-
vestigated here, using postnatal forebrain-restricted PS1 cKO
mice.
Our findings show that partial inactiva-
tion of -secretase by conditional inactiva-
tion of PS1 ameliorated amyloid-related
phenotypes displayed by APP transgenic
mice. Specifically, our biochemical and
histological analyses indicated that selec-
tive inactivation of PS1 in the cerebral cor-
tex reduced the accumulation of A pep-
tides and prevented amyloid plaque
formation and inflammatory responses as-
sociated with APP transgenic mice (Figs. 3,
4). These results are consistent with a pre-
vious report showing reduced A peptides
and amyloid deposition in another line of
APP transgenic mice with the use of a
neuronal-specific PS1 cKO mouse (Dew-
achter et al., 2002). Furthermore, our be-
havioral analysis that used the contextual
fear conditioning and serial spatial reversal
learning revealed that inactivation of PS1
rescued the hippocampal-dependent
learning and memory deficits of young
APP transgenic mice (Figs. 5, 6). Our ob-
servation that A-associated deficits
normally observed in two separate hip-
pocampal-dependent memory tasks were
rescued by limiting the synthesis of human
A in APP transgenic mice via PS1 inacti-
vation is consistent with a previous report
stating that germline disruption of the
BACE1 gene in another line of APP trans-
genic mice rescued memory deficits in so-
cial recognition and spatial alternation
tasks (Ohno et al., 2004).
The second key finding of our study is
that the improvement of the cognitive im-
pairment associated with APP Tg mice via
PS1 inactivation is age-related and tran-
sient. For example, the impairment of con-
textual memory exhibited by APP Tg mice
no longer was rescued by PS1 inactivation
in PS1 cKO;APP Tg mice at 6 months of
age. Furthermore, alterations in basal syn-
aptic transmission and/or LTP induction
observed in APP Tg mice also failed to be
rescued by PS1 inactivation in PS1 cKO;
APP Tg mice (Fig. 7). Our previous study
of PDAPP mice in the serial spatial reversal
task showed an age-related decline in per-
formance that could be observed over a
period of almost 1 year (G. Chen et al.,
2000). Thus older PS1 cKO;APP Tg mice at
15–17 months of age were tested in the
serial spatial reversal task, and the amelio-
ration of the learning deficits associated
with the APP transgenic mice by PS1 inac-
tivation was no longer statistically sig-
nificant. This age-related rescue of hip-
pocampal-dependent cognitive function
in PS1 cKO;APP Tg mice may explain the apparent discrepancies
between our findings and a previous report showing that inacti-
vation of PS1 in neurons of APP[V7171I] transgenic mice res-
cued LTP impairments but failed to rescue the impairment in
Figure 6. Age-dependent rescue of serial spatial learning in PS1 cKO;APP Tg mice. A, B, Control, PS1 cKO, APP Tg, and PS1
cKO;APP Tg mice at 3 months of age (A) and 15–17 months of age (B) were trained in the visible platform version of the water
maze for 5 d consecutively (4 trials/d). APP Tg and PS1 cKO;APP Tg mice showed normal performance in the cue task. The number
of mice used in each group is indicated in parentheses. C, Mice were trained in the serial spatial reversal task in a water maze for
10 d. Analysis of trials to reach criterion revealed no difference among control, PS1 cKO, and PS1 cKO;APP Tg groups ( p  0.10),
but these three groups took fewer trials to learn the five platform locations than the APP Tg group ( p  0.001). These data
indicate that PS1 cKO;APP Tg mice at 3 months of age exhibit a rescue of spatial working memory. D, Analysis of trials-to-criterion
of mice at 15–17 months of age indicated that performances of the PS1 cKO, APP Tg, and PS1 cKO;APP Tg mice did not differ from
each other ( p  0.10), and their performances were poorer than that shown by the control group ( p  0.05). E, Learning
capacity was measured as the total number of spatial reversal locations learned in 10 d. Analysis of learning capacity showed
similar learning capacity for the control, PS1 cKO, and PS1 cKO;APP Tg groups and reduced learning capacity in the APP Tg group
at 3 months of age ( p  0.001). These data indicate a rescue of learning capacity in PS1 cKO;APP Tg mice at 3 months of age. F,
The learning capacity of APP Tg, PS1 cKO;APP Tg, and PS1 cKO groups at 15–17 months of age did not differ significantly, but the
average performance of these three groups was significantly lower than that of the control group ( p  0.01). Data represent the
mean  SEM.
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spontaneous object recognition at 3– 6
months of age (Dewachter et al., 2002).
It may seem surprising that the learning
and memory deficits exhibited by old APP
transgenic mice are not ameliorated by the
prevention of A accumulation in PS1
cKO;APP Tg mice. However, any benefi-
cial effect on learning that results may be
more than offset by other biochemical
changes taking place in these older mice.
Several observations of this study point to
the possibility that age-dependent accu-
mulation of APP C-TFs, as a result of
-secretase inhibition, may underlie the
memory deterioration in older PS1 cKO;
APP Tg mice. Confocal and electron mi-
croscopy analyses showed marked accu-
mulation of APP C-TFs at synaptic
terminals in PS1 cKO;APP Tg mice (Fig.
2). The accumulation of APP C-TFs could
be caused by deficient trafficking and/or
processing of APP and APP C-TFs. Con-
sistent with this interpretation, PS1 has
been implicated previously in the traffick-
ing of APP (Naruse et al., 1998; Leem et al.,
2002; Cai et al., 2003). PS1 may be regulat-
ing the processing of APP and cleavage of
APP C-TFs in or near synaptic sites where
these precursors containing the entire A
domain accumulate (Schubert et al., 1991;
Buxbaum et al., 1998). Indeed, we found
recently that A42 peptides accumulate in
multivesicular bodies at neuronal pro-
cesses and synaptic compartments of APP
transgenic mice and AD brains (Takahashi
et al., 2002, 2004). It has been suggested
that the A released from presynaptic sites
is deposited in extracellular plaques (Bux-
baum et al., 1998; Lazarov et al., 2002).
Finally, a deleterious effect of abnormally
high levels of APP C-TFs on synaptic func-
tion is supported by previous findings
showing LTP and memory impairments in
mice injected with or expressing APP
C-TFs (Cullen et al., 1997; Nalbantoglu et
al., 1997; Choi et al., 2001).
An alternative explanation of the age-
dependent deterioration of contextual fear
conditioning and serial spatial reversal in
PS1 cKO;APP Tg mice is that inactivation
of PS1 itself causes cognitive impairments.
However, we have demonstrated previ-
ously, by using an intensive training pro-
tocol, that PS1 cKO mice perform simi-
larly to littermate controls in contextual
fear conditioning and spatial reference
memory (Saura et al., 2004), although they
do exhibit a spatial reference memory def-
icit under a more difficult training proto-
col (Yu et al., 2001). Furthermore, PS1
cKO mice exhibit normal synaptic trans-
mission and plasticity in the Schaffer col-
lateral pathway (Yu et al., 2001). These ob-
Figure 7. Similar hippocampal synaptic alterations in APP Tg and PS1 cKO;APP Tg mice. A, Basal synaptic transmission is
reduced in APP Tg and PS1 cKO;APP Tg mice at 6 months of age. The I/O slope was obtained by plotting the FV amplitude against
the initial slope of the evoked fEPSP in acute hippocampal slices of control, APP Tg, and PS1 cKO;APP Tg mice. The graph represents
the average slope of the I/O curves. *p  0.02; **p  0.005. B, The graph depicts the paired pulse response ratio (second
fEPSP/first fEPSP) obtained at different interstimulus intervals in 6-month-old mice. APP Tg and PS1 cKO;APP Tg mice show
normal PPF ( p  0.14). C, Left, Time course of the effects of five episodes of TBS on the fEPSP initial slope in 6-month-old mice.
Right, Examples of LTP induced in slices from control (top), APP Tg (middle), and PS1 cKO;APP Tg (bottom) mice. Superimposed
traces are averages of four consecutive responses recorded 1 min before (thin line) and 60 min after (thick line) TBS. APP Tg and PS1
cKO;APP Tg mice show impaired LTP. D, The graph represents the average slope of the I/O curves in 3-month-old mice. The average
of FV–fEPSP slopes in APP Tg and PS1 cKO;APP Tg mice is similar to that of control mice at 3 months of age ( p0.05). E, The graph
depicts the paired pulse response ratio obtained at different interstimulus intervals in 3-month-old mice. APP Tg, PS1 cKO;APP Tg,
and control mice show similar PPF ( p  0.13). F, Left, Time course of the effects of five episodes of TBS on the fEPSP initial slope
in 3-month-old mice. Right, Examples of LTP induced in slices from control (top), APP Tg (middle), and PS1 cKO;APP Tg (bottom)
mice. Superimposed traces are averages of four consecutive responses recorded 1 min before (thin line) and 60 min after TBS (thick
line). In B, C, E, F, the numbers of mice (left) and slices (right) are indicated in parentheses. Data represent the mean  SEM.
Calibration: (in C, F ) 0.5 mV, 5 ms.
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servations suggest that PS1 inactivation alone is unlikely to
account for the observed phenotype. Moreover, although it may
be argued that residual levels of A in the cortex of PS1 cKO;APP
Tg mice contribute to the age-dependent cognitive deterioration,
this is also unlikely, because similar residual levels of A40 and
A42 were found in these mice at 2–3, 6, and 17 months of age. It
is therefore reasonable to suggest that abnormal accumulation of
APP C-TFs in neurons of the cerebral cortex, especially in the
synaptic terminals, contributes to memory impairments in older
PS1 cKO;APP Tg mice. However, we cannot yet rule out the
possibility that long-term PS1/-secretase inactivation could
contribute to the described phenotype by the deficient processing
of other known or still unidentified synaptic substrates (Kim et
al., 2002; May et al., 2002; Marambaud et al., 2003; Schulz et al.,
2003).
Are presenilins potential drug targets for AD therapy? The
results presented here showing prevention of A accumulation
and amyloid deposition in PS1 cKO;APP Tg mice provide sup-
port for the view that targeting PS1 function or -secretase
activity could be an effective approach for anti-amyloidogenic
treatment. In addition, our extensive behavioral analysis demon-
strates that inactivation of PS1 can provide temporary benefits to
improve cognitive function in APP transgenic mice. Neverthe-
less, presenilins have many important physiological functions
ranging from synaptic plasticity to epidermal proliferation
(Doerfler et al., 2001; Xia et al., 2001; Qyang et al., 2004; Saura et
al., 2004; Tournoy et al., 2004), and complete loss of presenilin
function in the cerebral cortex, which is the most relevant ana-
tomical substrate for AD pathogenesis, leads to progressive mem-
ory loss and neurodegeneration (Saura et al., 2004). We recently
proposed that loss of presenilin function together with increases
in A peptides collectively could lead to memory loss and neuro-
degeneration in FAD (Saura et al., 2004). The finding that PS1
mutations devoid of -secretase activity are associated with fron-
totemporal dementia (Raux et al., 2000; Amtul et al., 2002; Der-
maut et al., 2004) also supports a possible link between loss of PS1
function and pathogenic mechanisms of dementia. The require-
ment of presenilins for synaptic plasticity, memory, and neuronal
survival is mediated partly by the regulation of the cAMP re-
sponse element-binding protein pathway, likely by -secretase-
dependent Notch cleavage and signaling (Saura et al., 2004).
Therefore, it is unlikely that -secretase inhibitors that affect
Notch signaling will be useful as potential drugs for AD treat-
ment. Alternatively, the development of specific -secretase in-
hibitors that inhibit A production, and specifically A42, with-
out disturbing other presenilin functions and specifically those
involved in synaptic function, still may provide a rational thera-
peutic approach for the treatment of AD. In conclusion, we have
demonstrated that conditional inactivation of PS1 in the postna-
tal forebrain efficiently prevents amyloid-associated neuropatho-
logical changes in APP transgenic mice. We provide evidence for
the first time that reduction of A as a result of -secretase inhi-
bition in vivo may provide transient cognitive improvements in
an amyloid mouse model. These findings raise the possibility that
-secretase inhibitors that specifically inhibit A generation
without altering other essential presenilin functions may provide
temporary therapeutic benefits.
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